Investor Presentation

Ref: ISLL:CH:2026 Date: 4th November, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB SUBJECT: INVESTOR PRESENTATION ON UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2026. Dear Sir / Ma'am, Pursuant to Regulation 30 and other applicable provisions, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith detailed Investors Presentation on Un-audited Financial Results for the quarter ended September 30, 2026. Kindly take the above information on record. Thanking you, For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer INVESTOR PRESENTATION Q2 & H1 FY27 | Results for the period ended 30 September 2026 MANAGEMENT COMMENTARY “Q2FY27 is a strong validation of the strategic choices we made earlier. Our transition from an API manufacturer to a focused FDF manufacturer, and the scale-up of operations on that platform, is now clearly visible in our performance. Operating income grew over 50% year-on-year, with operating EBITDA margin expanding to 18.02% and PAT margin to 13.21%, reflecting the strength of our business model. The scale-up of our operations is delivering operating leverage, while the shift in business mix is lifting margins. Raw material cost has come down as a share of revenue, and our growth is coming from core operations rather than other income. Sequentially, revenue and operating EBITDA both grew by over 25%, building on a strong Q1. This momentum carried through the first half, with H1FY27 operating revenue of ₹420.97 crore, up 35.79%, while operating EBITDA grew more than 4x. With a net-debt-free balance sheet, substantial cash and investments, and our ₹250 crore capex programme funded through internal accruals, we are well placed to scale. Supported by deeper own-brand penetration in key export markets and the ongoing Samba EU-GMP upgrade, we continue to expect FY27 revenue growth of more than 50%, a medium-term revenue CAGR of 20-25% and EBITDA margin expansion of 200-300 BPS. We remain focused on building a compliance-led, differentiated FDF platform and sustaining profitable growth.” N.R. Munjal Chairman and Whole Time Director EVOLUTION & TRANSFORMATION JOURNEY Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories Inspection Ltd. Divested API Unit Group Consolidation through merger Ind-Swift Laboratories Ltd. | Growth & Regulatory Milestones of Ind Swift Ltd 2006 2007-11 2012 2013-18 2019-22 GBU MHRA Health Day-1 Philipines, Dry Suspension Manufacturing Canada, Launch of Thailand, South & Shiftpack Plant ANVISA, Generic, Africa & FDA facility added Established Commissioning Atorvastatin Approval. & Health of Formulation Launched patented Canada Facility at Ivabradine approval Oxalate in Europe Jammu IND - SWIFT LABORATORIES LTD – “The Before State” DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers Leadership in macrolides & complex chemistry Regulatory approvals from USFDA, MHRA, PMDA, 26 70+ Largest drug ANVISA, TGA, SFDA, ROF, NCPHP, Health Canada, MoH manufacturer in Countries supplied Manufacturing Oman, CDSCO India, HLfGP-Germany, FDA India North India Blocks across regulated + Proven CRAMS capability with innovator pharmerging markets collaborations Core Business Capabilities • Complex chemistry API development & scale-up • Integrated CRAMS operations for innovator projects • Backward-integrated, cost-efficient manufacturing • Strong regulatory compliance track record TRANSACTION SUMMARY & FINANCIAL RESET Synthimed Labs Transaction Summary Strategic Rationale Debt Elimination: Proceeds used Transaction Value : Slump Sale : to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile to net ₹1,650 Cr debt-free Portfolio company of India Resurgence Fund (Bain Capital & Capital Reallocation: Resources Piramal) freed to invest in higher-margin formulation businesses 3 manufacturing sites with USFDA, Retained Stake PMDA, EDQM approvals Business Realignment: Strategic exit from capital-intensive API ISLL holds 7.80% equity in operations Currently valued at ₹8,000-9,000 Cr (USD 1 bn) Synthimed, continuing the stake in growing APIs. Value Creation: Framework created for sustainable growth. POST - TRANSFORMATION OVERVIEW Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 900+ 540+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Product registration Years of (Effective 31 March 2024, NCLT-approved). registrations globally owned by Ind-Swift Experience • Consolidation created a single, streamlined, formulation-focused listed entity. • Repositioned as a pure-play Finished Dosage Formulation (FDF) 2,100+ 1200+ 85+ company. Dossiers filed Team Size Countries • Net debt-free balance sheet enabling growth investments Presence • Facilities accredited by UK-MHRA, TGA, Health Canada, WHO-GMP, ROF Germany, SFDA-Saudi Arabia, NCPHP-Hungary, MOH-Oman etc. Post-Merger Business Structure (New Operating Model) Domestic Division International Division (GBU) • Ethical, Generics, P2P & others (Q-DEN / Nova.) • Presence across 85+ countries. • 260+ marketing teams covering 20,000 retailers & • Strong CMO relationships & regulated market 25,000+ doctors. penetration. • Network of 3,000 stockists and 14 C&F. • Extensive dossier pipeline supporting long-term growth. MANUFACTURING INFRASTRUCTURE Global Business Unit (GBU) Domestic Unit Derabassi, Punjab Samba, J&K • Strategic Status: 100% Export-Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Capabilities: Dedicated blocks for Oral Solid Dosages (Tablets, Capsules, Sachets). • Key Approvals: UK-MHRA, TGA, Health • Focus: Domestic formulations Canada, WHO-GMP, MoH (Ethical, Generics, P2P, & others.) • Capacity: High-volume output capable of • Scale: Spans 14,700 sq. meters. supporting >₹10 Billion+ Revenue reach. • Accreditations: WHO-GMP, ISO • Tablets: 9 Billion (9,000 Million) / Annum. 9001:2008 • Capsules: 120 Million / Annum. • Sachets: 150 Million / Annum. Acquired 18,000 sq. yds. of land in • Sticks: 184 Million / Annum. Derabassi earmarked for dedicated • Dry Powder in Bottles: 33 Million / Annum warehouse development. • Pellets: 30 Ton / Annum R&D CAPABILITES Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 70+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validation. Core Strengths & Competencies Key R&D Metrics (Post-Transformation) Strategic Achievements • Pharmacokinetic Profiling: Built analytical • Regulatory Compliance: Capability for CTD / • Global Filings: 2100+ dossiers filed across 85+ capability to profile advanced drug eCTD dossier preparation targeting UK, EU, countries. delivery systems, such as Gastro- Australia, and Canada. • Success Rate: 540+ Product registration owned by Resistant (GR), Delayed-Release (DR), • Tech Transfer: Integrated QMS framework Ind-Swift. Multi-Unit [Showing first 8,000 characters — download PDF for full document]